ICPT

Intercept Pharmaceuticals, Inc. (ICPT) | Rumor.io

Intercept Pharmaceuticals

ICPT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)20%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ICPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Nov 8

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. ($ICPT) in a deal that has closed, with the stock halted.
The acquisition was announced through a series of SEC filings, including SC 14D9/A, 8-K, and SC TO-T/A, detailing the completion of the tender offer.
The stock price of $ICPT was trading at $18.99 with a -0.05% change at the time of the acquisition announcement.

Generated by AI

Sentiment

Of the messages about ICPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	42.11% -31.33
Bearish	—	—	—	57.89% +31.33

Bullish· Sep 26

The buyout of ICPT at $19 offers a significant premium, with 82% above the previous price, and is considered a positive development for the bio market.
The acquisition of ICPT by Alfasigma is seen as a strategic move, expanding the company's global footprint in rare and serious liver diseases, and providing a new opportunity for growth.
The short interest in ICPT peaked before the buyout, suggesting that this may be a indicator for other companies, such as AUPH, which could also be subject to a buyout in the future.

Bearish· Sep 26

Intercept Pharmaceuticals ($ICPT) was sold for less than $1 billion, a significant decline from its peak market cap of over $8 billion.
The company's NASH (non-alcoholic steatohepatitis) program was a major disappointment, and the fibrate/OCA combo is now the focus, but it's unclear if it will be successful.
The stock's short interest is high, with 30% of its float sold short, which could lead to significant losses for short sellers if the stock price rises.

Generated by AI

Topics

Of the messages about ICPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	5.88%
Announcements	—	—	—	90.59%
Controversies	—	—	—	3.53%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Nov 3

Intercept Pharmaceuticals, Inc. (ICPT) reported Q3 earnings of -$0.11 EPS and $92.82M revenue, beating estimates.
ICPT's Q3 earnings beat estimate by $0.98, and revenue beat estimate by $8.19M, with a boost in 2021 Ocaliva sales guidance.
ICPT updated FY 2021 guidance to EPS and revenue guidance to $355 million-$370 million.

Analysts· Aug 20

Goldman Sachs downgraded Intercept Pharmaceuticals ($ICPT) to Sell from Neutral, with a lower price target of $10 from $17.
The downgrade was attributed to Goldman Sachs analyst Salveen Richter, who expressed concerns about the sustainability of the company's business model.
Intercept Pharmaceuticals' shares traded lower following the downgrade, with a significant price drop and increased short interest.

Announcements· Sep 26

Alfasigma to acquire Intercept Pharmaceuticals ($ICPT) for $19.00 per share in cash, expanding its global footprint in rare and serious liver diseases.
The acquisition represents an 82.0% premium to $ICPT's stock price, with a total value of $794 million and an implied 95% odds of success.
$ICPT's pipeline includes OCALIVA, approved for primary biliary cholangitis, with a CRL for NASH in June 2023, and an ongoing Phase 2 study with the OCA-bezafibrate combo.

Technical Analysis· Feb 21

The 2 lowest targets for ICPT among 19 published estimates average to $92, with a lower risk level (LR) of $91 and a lower risk average momentum (BAM) of $93.
ICPT has shown an inverse head and shoulders pattern, which could indicate a potential rebound, with some traders hoping to test the $93-$96 mark.
The stock has been experiencing a breakdown below its 20-day price channel, with recent technical alerts including a volume surge, falling below its 20 and 50-day moving averages, and a wide range bar.

Generated by AI

Community

Of the messages about ICPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	19.66%
Newcomers	—	0%	0%	80.34%

Regulars· Sep 26

$ICPT is being acquired by Alfasigma for $19.00 per share in cash, expanding Alfasigma's global footprint in rare and serious liver diseases.
The acquisition price is a significant discount to Intercept's peak market capitalization of over $8 billion, with the company's NASH program experiencing a major setback.
The deal marks the end of Intercept's commercial opportunities in NASH, but its PBC revenue and fibrate/OCA combo asset still hold potential for future growth.

Newcomers· Sep 27

Newcomers to the ICPT asset are expressing regret for selling too early, citing the price at which they sold.
ICPT's stock price has been impacted by a downgrade from B. Riley, with analysts citing concerns about the company's prospects.
Intercept Pharmaceuticals has agreed to a $794M buyout deal with Alfasigma, with some newcomers to the asset highlighting this development as a key factor in the company's stock price surge.

Generated by AI

Also Discussed

Investors talking about ICPT also mention

#	Name	Attention
1	GNFT - Genfit S.A.	——
2	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
3	Puma Biotechnology, Inc.PBYI	0%0
4	Galectin Therapeutics Inc.GALT	0.01%+0.01
5	BioMarin Pharmaceutical IncBMRN	0%+0
6	Gilead Sciences, Inc.GILD	0%-0.04
7	iShares Biotechnology ETFIBB	0.01%0
8	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
9	Acadia Pharmaceuticals Inc.ACAD	0%+0
10	RDUS - Radius Recycling, Inc.	——